- Home
- ASAN vs CDTX Comparison
ASAN vs CDTX Comparison
Compare ASAN & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | CDTX |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ASAN | CDTX |
|---|---|---|
| Price | $14.61 | $219.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $16.71 | ★ $128.75 |
| AVG Volume (30 Days) | ★ 4.9M | 2.3M |
| Earning Date | 12-02-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $773,570,000.00 | N/A |
| Revenue This Year | $10.81 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.47 | N/A |
| 52 Week Low | $11.58 | $15.22 |
| 52 Week High | $27.77 | $221.20 |
Technical Indicators
Market Signals| Indicator | ASAN | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 86.92 |
| Support Level | $12.52 | $219.76 |
| Resistance Level | $15.28 | $220.92 |
| Average True Range (ATR) | 0.65 | 0.83 |
| MACD | 0.31 | -3.22 |
| Stochastic Oscillator | 82.09 | 44.87 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a provider of collaborative work management software delivered via a cloud-based SaaS model. The firm's solution offers scalable, dynamic tools to improve the efficiency of project and process management across countless use cases, including marketing programs, managing IT approvals, and performance management. Asana's offering supports workflow management across teams, provides real time visibility into projects, and reporting and automation capabilities. The firm generates revenue via software subscriptions on a per seat basis.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.